Kí ni “Clear” túmọ̀ sí?
Eranko ko gbe iyipada. Kii yoo ni idagbasoke arun na ati pe kii yoo kọja lori rẹ.
Aja Aipe Adhesion Canine Leukocyte (CLAD)
Discover the importance of DNA testing for Canine Leukocyte Adhesion Deficiency (CLAD) in dogs. CLAD is a serious genetic disorder affecting the immune system, making dogs more susceptible to infections. Early detection through a simple DNA test can help pet owners make informed breeding decisions and ensure healthier puppies. Understanding CLAD allows for better management of affected dogs, improving their quality of life. This test is crucial for breeds prone to this condition, such as Irish Setters. Protect your furry friend with proactive measures by opting for a CLAD DNA test today. Invest in your dog’s health and well-being—knowledge is power!
Kukuru: CLAD
Iyipada ti a ṣe ayẹwo: ITGB2 c.107G>C
Ogún: Idaduro Aifọwọyi
Adape
CLAD
Ti ṣe akiyesi igbohunsafẹfẹ
Isẹgun idibajẹ
Isọdi isẹgun
Awọn Arun Ajẹsara
Iyipada atupale
ITGB2 c.107G>C
p.(C36S)
p.(C36S)
Ipo ti ilẹ-iní
Idaduro Aifọwọyi (Pari)
Akopọ idanwo:
Canine Leukocyte Adhesion Deficiency (CLAD) is a genetic disorder that affects the immune system of dogs, particularly prevalent in certain breeds like the Irish Setter. This condition impairs the ability of white blood cells to adhere to blood vessel walls, leading to increased susceptibility to infections. A DNA test can identify carriers and affected dogs, helping breeders make informed decisions to reduce the incidence of CLAD in future generations. Early detection through testing is crucial for managing the health of affected dogs. Responsible breeding practices can help eliminate this debilitating condition from the gene pool.
Wa lati idii: Basic
Idanwo DNA yii wa pẹlu ti o bẹrẹ lati idii wa Basic - ati ki o jẹ tun apa ti awọn akopọ Basic, Standard, Advanced, Complete.
Wo Awọn akopọ Idanwo DNA →Yan idii ti o baamu ibisi rẹ dara julọ tabi ilana ilera ti awọn ẹranko rẹ.
Understanding Canine Leukocyte Adhesion Deficiency (CLAD)
Canine Leukocyte Adhesion Deficiency (CLAD) is a genetic disorder primarily affecting the immune system of dogs. It is caused by a mutation in a specific gene that is responsible for the development and function of leukocytes, or white blood cells. This condition leads to an inability of leukocytes to adhere to blood vessel walls, which is crucial for their migration to sites of infection or inflammation.
Clinical Signs of CLAD
Dogs affected by CLAD typically exhibit a range of clinical signs due to their compromised immune response. Common symptoms include recurrent infections, poor wound healing, and chronic inflammation. Affected dogs may also show signs of systemic illness, such as fever, lethargy, and weight loss. The severity of these symptoms can vary widely among individuals, depending on the extent of their immune dysfunction.
Diagnosis of CLAD
The diagnosis of CLAD is primarily achieved through genetic testing. A DNA test specifically designed to identify the mutation associated with CLAD can confirm the diagnosis. This test is crucial for breeders and dog owners to understand the genetic status of their dogs and to make informed breeding decisions. Early detection can also help in managing the health of affected dogs more effectively.
Management and Treatment
Currently, there is no cure for CLAD; however, management strategies can be employed to improve the quality of life for affected dogs. Treatment often involves prompt and aggressive management of infections with antibiotics and supportive care. Additionally, owners may need to take extra precautions to minimize exposure to pathogens, such as avoiding dog parks or other areas where dogs congregate.
Importance of Genetic Testing
Genetic testing for CLAD is vital for responsible breeding practices. By identifying carriers and affected individuals, breeders can make informed decisions to avoid producing affected puppies. This not only helps in reducing the prevalence of the condition in the population but also promotes overall canine health and welfare.
Ipari
Canine Leukocyte Adhesion Deficiency is a serious genetic condition that poses significant health challenges for affected dogs. Understanding this disorder, recognizing its symptoms, and utilizing genetic testing are essential steps in managing the condition and ensuring the health of future generations of dogs. By prioritizing genetic health, dog owners and breeders can contribute to a healthier canine population.
A ṣe idanimọ ajọbi fun idanwo naa: Aipe Adhesion Canine Leukocyte (CLAD)
- Irish Red and White Setter
- Irish Setter
- Irishdoodle
🧬 Interpretation of genotypes CLAD
Genotype
Ipo
🟡 N/N
Ti kii-ti ngbe - Ko si Ewu
🟡 N/CLAD
Carrier - No Risk
❌ CLAD/CLAD
Foju - Ni Ewu
FAQ: oye itumọ
Ṣe “Olugbese” ṣe pataki?
Rara. Eranko naa ni ilera ni gbogbogbo ṣugbọn o le tan iyipada si rẹ ọmọ.
Ohun ti o ba ti eranko ti wa ni "Fara"?
O gbe awọn ẹda ti o yipada meji. Awọn ami ile-iwosan ni a nireti da lori arun na. Ko yẹ ki o jẹ ajọbi.
Kini idi ti iyatọ wa laarin ọkunrin / obinrin?
Diẹ ninu awọn arun ti wa ni ibalopo-ti sopọ mọ, ki wọn ikosile yatọ da lori awọn ibalopo eranko.
Sọtẹlẹ Awọn ọmọ
N/N (ti-kii-ti-ngbe)
N/CLAD (Olugbeja)
CLAD/CLAD (fowo)
Idanwo DNA FAQ
Kini idanwo DNA yii ṣe awari?
This DNA test detects the mutation associated with Canine Leukocyte Adhesion Deficiency (CLAD) in order to identify clear, carrier, or at-risk animals.
Kini idi ti idanwo ẹranko ibisi kan?
Idanwo DNA ṣe iranlọwọ fun awọn ajọbi gbero awọn ibarasun ailewu ati dinku eewu ti gbigbe iyipada si awọn ọmọ.
Kini ipo ogún ti idanwo yii?
Ipo ogún ti a royin fun idanwo yii jẹ Recessive Autosomal.
Iyipada wo ni a ṣe atupale ninu idanwo yii?
This test analyses the mutation ITGB2 c.107G>C.
Njẹ ẹranko ti ngbe ni dandan kan bi?
Ko dandan. Itumọ da lori ilana ogún ati genotype abajade.
Awọn itọkasi
Kijas J M, Bauer T R Jr, Gäfvert S, Marklund S, TrowaldWigh G, Johannisson A, Hedhammar A, Binns M, Juneja R K, Hickstein D D, Andersson L. A missense mutation in the beta-2 integrin gene (ITGB2) causes canine leukocyte adhesion deficiency. Genomics. 1999 Oct 1;61(1):101-7. doi: 10.1006/geno.1999.5948.